STOP-ACEi 试验:晚期进展性 CKD 停用 ACEi 与 ARB 的比较
STOP-ACEi 开放标签试验纳入 eGFR<30ml/min/1.73m² 的进展性 CKD 患者,随机停用或继续 RASi,3 年 eGFR 相似。基线停 ACEi 者 99 例、继续 123 例;停 ARB 者 104 例、继续 77 例。停 ACEi 者肾衰竭/KRT 风险较高(HR 1.52),但试验非为比较两药而设计。
要点
- 晚期进展性 CKD 停用 ACEi 或 ARB 均未减缓 3 年 eGFR 下降。
- 停 ACEi 者肾衰竭/KRT 发生率为 65%,继续者为 54%(HR 1.52)。
- 停 ARB 者肾衰竭/KRT 发生率为 60%,与继续者相同(HR 1.23)。
核心结论
- 停用 ACEi 或 ARB 均未减缓晚期进展性 CKD 患者 eGFR 下降速度。
- 停用 ACEi 对肾脏结局的不利影响似乎大于停用 ARB,但试验未设计也未把握度检验两药间差异。
研究设计与样本
- STOP-ACEi 为开放标签随机试验,纳入 eGFR<30ml/min/1.73m² 且进展性 CKD 的患者,随机停用或继续 RASi。
- 基线停 ACEi 99 例、继续 ACEi 123 例;停 ARB 104 例、继续 ARB 77 例。
- 主要结局为 3 年时 eGFR;同时评估肾衰竭、eGFR 下降>50% 或肾脏替代治疗(KRT)的复合结局。
主要发现
- 3 年时 eGFR 在停用与继续 ACEi 或 ARB 的患者中相似。
- 肾衰竭或启动 KRT:停 ACEi 者 65% vs 继续 ACEi 者 54%(停用 HR 1.52,95%CI 1.07–2.16);停 ARB 者 60% vs 继续 ARB 者 60%(停用 HR 1.23,95%CI 0.83–1.81)。
- 肾衰竭/启动 KRT 或 eGFR 下降>50%:停 ACEi 者 71% vs 继续 ACEi 者 59%(停用 RR 1.19,95%CI 1.00–1.41);停 ARB 者 65% vs 继续 ARB 者 69%(停用 RR 0.96,95%CI 0.79–1.16)。
临床怎么用
- 对于 eGFR<30ml/min/1.73m² 的进展性 CKD 患者,停用 ACEi 或 ARB 均未显示减缓 eGFR 下降。
- 停用 ACEi 者肾衰竭/KRT 风险高于继续者(HR 1.52),但试验未设计比较 ACEi 与 ARB 差异。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the STOP-ACEi trial, the outcome was similar whether or not renin-angiotensin system inhibitors (RASi) were discontinued. We now investigate whether the effect of withdrawing angiotensin converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARBs) differed. In this open label trial patients with estimated glomerular filtration rates (eGFR) under 30ml/min per 1.73 m2 and progressive chronic kidney disease (CKD) were randomized to stop or continue RASi. The primary outcome was eGFR at three years. The composite of kidney failure, over 50% fall in eGFR, or kidney replacement therapy (KRT) was also assessed. Of patients randomized, 99 stopped and 123 patients continued ACEi while 104 stopped and 77 continued ARB at baseline. At three years, the eGFR was similar whether or not patients were withdrawn from ACEi or from ARB. Kidney failure or initiation of KRT occurred in 65% of those stopping and 54% continuing ACEi (hazard ratio if stopped, 1.52; 95% Confidence Interval, 1.07 to 2.16) and in 60% on an ARB regardless of randomized group (hazard ratio if stopped, 1.23; 0.83 to 1.81). Kidney failure/Initiation of KRT with over 50% decline in eGFR occurred in 71% of those stopping and 59% continuing ACEi (relative risk if stopped, 1.19; 95% CI, 1.00 to 1.41) and in 65% stopping and 69% continuing ARB (relative risk if stopped, 0.96; 0.79 to 1.16). Thus, neither discontinuing ACEi nor ARB slowed the rate of decline in eGFR. Although discontinuation of ACEi appeared to have more unfavorable effects on kidney outcomes than stopping ARB, the trial was neither designed nor powered to show differences between agents.
引用
- Bhandari S, Mehta S, Khawaja A, et al. Evaluation of the stopping angiotensin converting enzyme inhibitor compared to angiotensin receptor blocker (STOP ACEi trial) in advanced and progressive chronic kidney disease. Kidney Int. 2023. PMID: 37783444. doi:10.1016/j.kint.2023.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。